Ark Therapeutics Group PLC Interim Management Statement (8370G)
May 13 2014 - 2:00AM
UK Regulatory
TIDMAKT
RNS Number : 8370G
Ark Therapeutics Group PLC
13 May 2014
Ark Therapeutics Group plc
Interim Management Statement and Notice of Annual General
Meeting
13 May 2014 - Ark Therapeutics Group plc ("Ark" or the
"Company") today publishes its interim management statement for the
period from 1 January 2014 to date.
-- On 28 March 2014, we were pleased to announce that the
Company had signed heads of terms in connection with the possible
acquisition of a revenue-generating and profitable UK-based private
company in the healthcare support services sector ("Target").
The transaction would be structured by way of an acquisition of
the Target by Ark in consideration for the issue of new Ark shares
to the shareholders of the Target. Due to its size in relation to
Ark, the proposed acquisition of the Target would constitute a
'reverse takeover' for the purposes of the Listing Rules.
In response to a request by the Company, the UK Listing
Authority suspended the listing of Ark's Premium listed shares on
the Main Market of the London Stock Exchange on 28 March 2014
pending publication of the required shareholder documents.
Shareholder approval would be required to approve the acquisition
of the Target which would be sought at a general meeting to be
convened in due course, after which the Company would also expect
to seek a lifting of the trading suspension.
The Board will make further announcements in due course.
-- On 30 April 2014, the Company announced its financial results
for the year ended 31 December 2013:
-- Total revenues and other income for the year ended 31
December 2013 of GBP0.3m (31 December 2012: GBP1.9m)
-- Net assets at 31 December 2013 of GBP0.9m (31 December 2012:
net liabilities of GBP0.2m)
-- Cash and short-term deposits of GBP0.8m (31 December 2012: GBP1.7m)
-- Profit for the year after tax was GBP1.1m (31 December 2012:
loss after tax was GBP2.5m)
The Company's Annual General Meeting will be held at 2.30 pm on
30 June 2014 at the offices of Ashurst LLP, Broadwalk House, 5
Appold Street, London EC2A 4HA.
For further information please contact:
Ark Therapeutics Group plc Tel: +44 (0)203 755 5160
Iain G Ross, Non-Executive Chairman
David Venables, Non-Executive
Director
This announcement includes "forward-looking statements" which
include all statements other than statements of historical facts,
including, without limitation, those regarding Ark's financial
position, business strategy, plans and objectives of management for
future operations, and any statements preceded by, followed by or
that include forward-looking terminology such as the words
"targets", "believes", "estimates", "expects", "aims", "intends",
"will", "can", "may", "anticipates", "would", "should", "could" or
similar expressions or the negative thereof. Such forward-looking
statements involve known and unknown risks, uncertainties and other
important factors beyond Ark's control that could cause the actual
results, performance or achievements of Ark to be materially
different from future results, performance or achievements
expressed or implied by such forward-looking statements. Such
forward-looking statements are based on numerous assumptions
regarding Ark's present and future business strategies and the
environment in which Ark will operate in the future. These
forward-looking statements speak only as at the date of this
announcement. Ark expressly disclaims any obligation or undertaking
to disseminate any updates or revisions to any forward-looking
statements contained in this announcement to reflect any change in
Ark's expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
As a result of these factors, readers are cautioned not to rely on
any forward-looking statement.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IMSGGUWGAUPCGUP
Premier Veterinary (LSE:PVG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Premier Veterinary (LSE:PVG)
Historical Stock Chart
From Jul 2023 to Jul 2024